A Closer Look at the Most Recent NCCN Guidelines for Bladder Cancer

The treatment landscape for patients with bladder cancer has rapidly changed with the addition of PD-1 and PD-L1 inhibitors approved for urothelial carcinoma, antibody drug conjugates like enfortumab vedotin-ejfv (Pacdev), and also targeted agents such as erdafitinib (Balversa) for patients with select FGFR mutations.